Xenetic BioSciences Inc. (NASDAQ:XBIO) Stock Sees Solid Buying Interest: Buy Now?

August 11, 2021

Xenetic BioSciences Inc. (NASDAQ:XBIO) jumped 14%. Recently, the company signed a sale and purchased a definitive agreement to purchase 4.63 million of its common shares by a healthcare-focused institutional investor. The company is offering the shares at $2.7 per share in an at-the-market private placement under the Nasdaq rules. Equally, the company agreed to provide the investor share purchase warrants to buy 4.63 million common shares. Notably, the contracts have…


Xenetic Biosciences (NASDAQ:XBIO) Stock Sees High Volatility: How to Trade Now?

August 2, 2021

Biopharmaceutical company, Xenetic Biosciences (NASDAQ:XBIO), on July 31, 2021 closure of previously announced private placement. This would be with single healthcare-focused institutional investor for 4,629,630 shares of the common stock. Xenetic focuses on a personalized CAR T platform technology for targeting patient and tumor specific neoantigens. The proceeds will be about $12.5 million before deducting placement agent fees and other offering expenses.The company issued to investor warrants for buying 4,629,630…


Xenetic Biosciences Inc (NASDAQ:XBIO) Stock Slumps 23% On Profit Booking

July 31, 2021

The week did not end on the right note for Xenetic Biosciences Inc (NASDAQ:XBIO) as the biopharmaceutical firm saw its stock crash by as much as 23% on Friday. There was no fresh news about the company yesterday but earlier on in the week the company had made a key announcement that investors need to take a look into. This past Wednesday the company announced that it successfully completed the…